Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Data unavailable.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 8 Oct 2018 | GIGANTIC ENTERPRISES | Bulk | Sell | 58,336 | 11.2200 | BSE |
| 8 Oct 2018 | GIGANTIC ENTERPRISES | Bulk | Buy | 117,693 | 11.1900 | BSE |
| 8 Oct 2018 | SOUMENDRA DAS | Bulk | Sell | 118,186 | 11.1700 | BSE |
| 15 Jan 2018 | DECCAN ENTERPRISES | Bulk | Sell | 188,950 | 21.1600 | BSE |
| 2 Jan 2018 | PADMA SINGH | Bulk | Sell | 238,686 | 22.2700 | BSE |
| 30 Oct 2017 | ADITYA NARAYAN SINGH | Bulk | Sell | 125,000 | 20.9000 | BSE |
| 30 Oct 2017 | MAHESH OMPRAKASH KHANDELWAL | Bulk | Buy | 178,237 | 21.2100 | BSE |
| 30 Oct 2017 | MAHESH OMPRAKASH KHANDELWAL | Bulk | Sell | 178,237 | 21.2500 | BSE |
| 25 Oct 2017 | ADITYA NARAYAN SINGH | Bulk | Sell | 202,785 | 23.2900 | BSE |
| 25 Jun 2015 | BP FINTRADE PRIVATE LIMITED | Bulk | Buy | 231,121 | 15.6100 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 7 Aug 2008 | Agm/Dividend - 10% | — | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from CELESTIAL LABS LTD. to Celestial Biolabs Limited |
| 17 May 2024 | OTHER | Annual General Meeting |
| 27 Sep 2022 | OTHER | Annual General Meeting |
| 17 Jun 2022 | OTHER | Annual General Meeting |
| 25 Sep 2018 | OTHER | Annual General Meeting |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 16 Oct 2024 | Delisting | Members of the Exchange are hereby informed about the delisting of equity shares of Celestial Biolabs Limited w.e.f. October 17, 2024 in terms of Rule 21(2) (b) of the Securities Contracts (Regulations) Rules 1957. |
| 23 Jul 2024 | Appointment | Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Dattatreya Rao as Executive Director of the company w.e.f. April 22, 2024. |
| 30 May 2024 | Board meeting Cancelled | This is to inform you that the Board Meeting of the company which was scheduled on 30.05.2024 stand cancelled due to non-finalization of accounts |
| 23 May 2024 | Shareholders meeting | Celestial Biolabs Limited has informed the Exchange regarding voting results of Annual General Meeting held on May 23, 2024 |
| 23 May 2024 | Shareholders meeting | Celestial Biolabs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on May 23, 2024 |
| 23 May 2024 | Shareholders meeting | Celestial Biolabs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on May 23, 2024 |
| 16 May 2024 | Disclosure under SEBI Takeover Regulations | Celestial Biolabs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
| 14 May 2024 | Clarification - Financial Results | The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited. |
| 10 May 2024 | Clarification - Financial Results | The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited. |
| 10 May 2024 | Clarification - Financial Results | The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
